Precigen, Inc. (NASDAQ: PGEN) is a clinical-stage biotechnology company headquartered in Germantown, Maryland, that specializes in the development and commercialization of precision gene and cell therapies. Originally founded as Intrexon Corporation in 1998 by entrepreneur Randal Kirk, the company rebranded to Precigen in 2019 to reflect its concentrated focus on human health and immuno-oncology. Leveraging proprietary technologies such as AAV-based gene delivery platforms and engineered cell therapy systems, Precigen aims to address unmet medical needs in oncology, infectious diseases and inherited disorders.
Precigen’s lead clinical programs include PRGN-3006, a modular chimeric antigen receptor (CAR) T-cell therapy targeting acute myeloid leukemia, and PRGN-2009, an investigational therapeutic for HPV-driven malignancies. In addition, the company is advancing gene-editing strategies for sickle cell disease and other hematologic conditions. Its preclinical portfolio spans novel vector design, synthetic biology approaches and next-generation immunomodulators, all designed to improve specificity, efficacy and safety of treatments in both solid tumors and rare genetic diseases.
With research facilities in Maryland and a manufacturing center in Germantown, Precigen collaborates with academic institutions, contract development partners and global regulators to support its development programs. The company’s leadership team is headed by President and CEO Cedrik Britten, supported by Executive Chair Dr. Helen Sabzevari, MD, who brings extensive experience in oncology drug development. As a publicly traded entity on the Nasdaq exchange, Precigen combines a rich scientific heritage with a streamlined corporate structure dedicated to bringing transformative therapies to patients worldwide.
AI Generated. May Contain Errors.
Free PGEN Stock Alerts